Background: Unique receptor involved in leukemogenesis is CD85k;an immuneglobulin receptor for immune tolerance, CD36 is glycoprotein mediates cellular adhesion and metastatic spread, CD14, CD15 considered common mono...Background: Unique receptor involved in leukemogenesis is CD85k;an immuneglobulin receptor for immune tolerance, CD36 is glycoprotein mediates cellular adhesion and metastatic spread, CD14, CD15 considered common monocytic markers. Aims: to investigate CD85k with monocytic lineage involved leukemia (MLIL) markers in leukemia pathogenesis and clinical presentation. Patients and Methods: 47 patients (32 diagnosed acute myeloid leukemia (AML);15 non-malignant hematological disease as a control), were included, aged from 2 to 80 years, all subjected to peripheral blood (P.Bl) and bone marrow (B.M) examination, immunophenotyping (IPT) using FASC Canto four color flow cytometer (FCM) Becton Dickenson (BD) USA, for CD13, CD33, MPO, HLA-DR, CD34, CD38, CD117, CD14, CD15 and CD36 the Mo Abs supplied by B.D Bioscience, and anti CD85k Mo Abs by Aveda de Coimbra Flamenco, reference No. 1399990130. Results: Frequency of CD85k is 19/32 (59.37%) of AML;14/14 (M4/M5) 100% positive CD85k, insignificant correlations of CD85k to sex, lymphadenopathy or organomegaly, platelets count and P.Bl blast (P > 0.05), significant to age 50,000 × 109/l, Hb 0.05). Conclusion: Although CD85k is MLIL associated marker, it is not correlated with other MLIL markers with frequency 100% in MLIL and 59.37% in AML, age predisposition is <35 years with no sex variation, significant correlation to progenitor and myeloid markers, it’s a crucial role in leukemogenesis biology, not in clinical presentations, considered good follow up predictor MLIL marker.展开更多
Inhibitory leukocyte immunoglobulin-like receptors(LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs(ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, ...Inhibitory leukocyte immunoglobulin-like receptors(LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs(ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, non-receptor type 6(PTPN6, SHP-1), protein tyrosine phosphatase, non-receptor type 6(PTPN6, SHP-2), or Src homology 2 domain containing inositol phosphatase(SHIP) to negatively regulate immune cell activation. These receptors are known to play important regulatory roles in immune and neuronal functions. Recent studies demonstrated that several of these receptors are expressed by cancer cells. Importantly, they may directly regulate development, drug resistance, and relapse of cancer, and the activity of cancer stem cells. Although counterintuitive, these findings are consistent with the generally immune-suppressive and thus tumor-promoting roles of the inhibitory receptors in the immune system. This review focuses on the ligands, expression pattern, signaling, and function of LILRB family in the context of cancer development. Because inhibition of the signaling of certain LILRBs directly blocks cancer growth and stimulates immunity that may suppress tumorigenesis, but does not disturb normal development, LILRB signaling pathways may represent ideal targets for treating hematological malignancies and perhaps other tumors.展开更多
目的：探讨脓毒症单核细胞表达ILT4的生物学行为和效应，及对于预后的影响。方法：选取BALB/c、BALB/c ILT4–/–雄性小鼠，CLP复制脓毒症模型。用流式细胞仪定量检测CLP术后24h单核细胞ILT4、MHC-Ⅱ表达水平；用ELISA法检测各组0、6、1...目的：探讨脓毒症单核细胞表达ILT4的生物学行为和效应，及对于预后的影响。方法：选取BALB/c、BALB/c ILT4–/–雄性小鼠，CLP复制脓毒症模型。用流式细胞仪定量检测CLP术后24h单核细胞ILT4、MHC-Ⅱ表达水平；用ELISA法检测各组0、6、12、24h血清IL-6、TNF-α浓度；并观察168h内生存预后。 结果：CLP术后24小时脓毒症小鼠外周单核细胞高度表达ILT4分子 （193.50 ± 52.54 vs. 1292.00 ± 143.70, p 〈 0.05） ；较WT组ILT4–/–小鼠外周单核细胞表达MHC-Ⅱ比率明显增高（24.25± 6.76% vs. 49.38 ±5.66%, p 〈 0.05） 。CLP术后24h血清IL-6显著增高（54.25± 20.04 vs. 470.75±88.03, p 〈 0.05），ILT4敲除后很大程度的抑制这一趋势（470.75±88.03 vs. 241.25 ± 45.10, p 〈 0.05）；但对TNF-α表达无显著性干扰（53.13 ±5.49 vs. 50.88 ±6.38, p〉 0.05）。且ILT4–/–小鼠CLP术后生存率WT明显增加（p 〈 0.05）。结论：脓毒症时单核细胞高表达ILT4，与高IL-6水平及低MHC-Ⅱ表达率相关，导致死亡率增加。展开更多
文摘Background: Unique receptor involved in leukemogenesis is CD85k;an immuneglobulin receptor for immune tolerance, CD36 is glycoprotein mediates cellular adhesion and metastatic spread, CD14, CD15 considered common monocytic markers. Aims: to investigate CD85k with monocytic lineage involved leukemia (MLIL) markers in leukemia pathogenesis and clinical presentation. Patients and Methods: 47 patients (32 diagnosed acute myeloid leukemia (AML);15 non-malignant hematological disease as a control), were included, aged from 2 to 80 years, all subjected to peripheral blood (P.Bl) and bone marrow (B.M) examination, immunophenotyping (IPT) using FASC Canto four color flow cytometer (FCM) Becton Dickenson (BD) USA, for CD13, CD33, MPO, HLA-DR, CD34, CD38, CD117, CD14, CD15 and CD36 the Mo Abs supplied by B.D Bioscience, and anti CD85k Mo Abs by Aveda de Coimbra Flamenco, reference No. 1399990130. Results: Frequency of CD85k is 19/32 (59.37%) of AML;14/14 (M4/M5) 100% positive CD85k, insignificant correlations of CD85k to sex, lymphadenopathy or organomegaly, platelets count and P.Bl blast (P > 0.05), significant to age 50,000 × 109/l, Hb 0.05). Conclusion: Although CD85k is MLIL associated marker, it is not correlated with other MLIL markers with frequency 100% in MLIL and 59.37% in AML, age predisposition is <35 years with no sex variation, significant correlation to progenitor and myeloid markers, it’s a crucial role in leukemogenesis biology, not in clinical presentations, considered good follow up predictor MLIL marker.
基金supported b y the Na tional In stitu te o f Health(1R01CA172268)the Leukemia&Lymphoma Society(1024-14+7 种基金TRP-6024-14)the Robert A.Welch Foundation(I-1834)the Cancer Prevention and Research Institute of Texas(RP140402 and DP150056)the Innovation Program of Shanghai Municipal Education Commission(13G20)the Program for Professor of Special Appointment(Eastern Scholar)at Shanghai Institutions of Higher Learningthe National Natural Science Foundation of China(813706548142200181471524)
文摘Inhibitory leukocyte immunoglobulin-like receptors(LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs(ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, non-receptor type 6(PTPN6, SHP-1), protein tyrosine phosphatase, non-receptor type 6(PTPN6, SHP-2), or Src homology 2 domain containing inositol phosphatase(SHIP) to negatively regulate immune cell activation. These receptors are known to play important regulatory roles in immune and neuronal functions. Recent studies demonstrated that several of these receptors are expressed by cancer cells. Importantly, they may directly regulate development, drug resistance, and relapse of cancer, and the activity of cancer stem cells. Although counterintuitive, these findings are consistent with the generally immune-suppressive and thus tumor-promoting roles of the inhibitory receptors in the immune system. This review focuses on the ligands, expression pattern, signaling, and function of LILRB family in the context of cancer development. Because inhibition of the signaling of certain LILRBs directly blocks cancer growth and stimulates immunity that may suppress tumorigenesis, but does not disturb normal development, LILRB signaling pathways may represent ideal targets for treating hematological malignancies and perhaps other tumors.
文摘目的：探讨脓毒症单核细胞表达ILT4的生物学行为和效应，及对于预后的影响。方法：选取BALB/c、BALB/c ILT4–/–雄性小鼠，CLP复制脓毒症模型。用流式细胞仪定量检测CLP术后24h单核细胞ILT4、MHC-Ⅱ表达水平；用ELISA法检测各组0、6、12、24h血清IL-6、TNF-α浓度；并观察168h内生存预后。 结果：CLP术后24小时脓毒症小鼠外周单核细胞高度表达ILT4分子 （193.50 ± 52.54 vs. 1292.00 ± 143.70, p 〈 0.05） ；较WT组ILT4–/–小鼠外周单核细胞表达MHC-Ⅱ比率明显增高（24.25± 6.76% vs. 49.38 ±5.66%, p 〈 0.05） 。CLP术后24h血清IL-6显著增高（54.25± 20.04 vs. 470.75±88.03, p 〈 0.05），ILT4敲除后很大程度的抑制这一趋势（470.75±88.03 vs. 241.25 ± 45.10, p 〈 0.05）；但对TNF-α表达无显著性干扰（53.13 ±5.49 vs. 50.88 ±6.38, p〉 0.05）。且ILT4–/–小鼠CLP术后生存率WT明显增加（p 〈 0.05）。结论：脓毒症时单核细胞高表达ILT4，与高IL-6水平及低MHC-Ⅱ表达率相关，导致死亡率增加。
